Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Aizenbud L, Gaiger N, Perdigoto A, Mann J, Torres M, Boland G, Lawless A, Silverman S, Schoenfeld D, Destina J, Hasson N, Tran T, Hurwitz M, Austin M, Sullivan R, Herold K, Kluger H. Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. Journal For ImmunoTherapy Of Cancer 2025, 13: e012358. PMID: 40935567, DOI: 10.1136/jitc-2025-012358.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsICI-induced colitisICI-induced hypophysitisHLA-G</i>Non-overlapping cohortsInterferon-gRisk of immune-related adverse eventsExpression of class I major histocompatibility complexClass I MHC expressionGeneral populationICI-treated patientsPeripheral blood mononuclear cellsMissense variantsInsulin-dependent diabetes mellitusSurvival of patientsCohort of patientsBlood mononuclear cellsClass I major histocompatibility complexGermline missense variantsClass I MHC moleculesMessenger RNA expressionCheckpoint inhibitorsThyroid patientsAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply